Skip Navigation

Annals of Oncology 2005 16(Supplement 4):iv110-iv115; doi:10.1093/annonc/mdi919
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gridelli, C.
Right arrow Articles by Colucci, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gridelli, C.
Right arrow Articles by Colucci, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Invited Paper

Italian clinical research in non-small-cell lung cancer

C. Gridelli1,, A. Rossi1, D. Galetta2, P. Maione1, C. Ferrara1, C. Guerriero1, F. Del Gaizo1, D. Nicolella1, G. Colantuoni, V. Gebbia3 and G. Colucci2

1 Division of Medical Oncology, ‘S.G. Moscati’ Hospital, Avellino; 2 Dept. of Medical Oncology; Oncology Institute, Bari; 3 Division of Medical Oncology, La Maddalena Hospital, Palermo, Italy

Correspondence to: Dr Cesare Gridelli, Division of Medical Oncology, ‘S.G. Moscati’ Hospital, Contrada Amoretta, 83100, Avellino, Italy. Tel: +39 0825 203573; Fax: +39 0825 203556; Email: cgridelli{at}libero.it

Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15–20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC.

Key words: Italian clinical research, NSCLC, lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.